PROMISE Registry to Evaluate PSMA-PET Imaging and Outcomes in Prostate Cancer Patients Assessing Prognosis and Survival Across Different Disease Stages

What this Trial Is About

Researchers are studying prostate cancer patients who have undergone PSMA PET imaging, using PROMISE criteria to standardize disease staging. The study aims to assess how well PSMA PET predicts survival outcomes and compares its prognostic value with other clinical scores across different stages of prostate cancer. This research addresses the need for better risk prediction to guide treatment and study design. This observational study includes adult men with biopsy-confirmed prostate cancer who had PSMA PET scans for initial staging or restaging at any disease stage. Data on these patients will be collected repeatedly every 3 to 6 months and entered into a central database. The study includes patients with at least 3 years of survival follow-up and excludes those with neuroendocrine prostate cancer or other metastatic cancers. Participants will provide data over up to 10 years, including survival and disease progression information. Researchers will analyze these data to evaluate associations between PSMA PET findings and overall survival as the primary outcome, with metastasis-free survival as a secondary outcome. The study monitors how PSMA PET results relate to clinical management and patient characteristics, helping improve prognostic tools for prostate cancer.

PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer